Lyn C Guenther1,2, Rod Kunynetz3, Charles W Lynde4, R Gary Sibbald5,6, John Toole6, Ronald Vender7,8, Catherine Zip9. 1. 1 Guenther Research Inc., London, ON, Canada. 2. 2 Western University, London, ON, Canada. 3. 3 Ultranova Clinical Trials and Probity Medical Research, Barrie, ON, Canada. 4. 4 Department of Medicine, University of Toronto, Toronto, ON, Canada. 5. 5 Della Lana Faculty of Public health and Faculty of Medicine, University of Toronto, Mississauga, ON, Canada. 6. 6 University of Manitoba, Winnipeg, MB, Canada. 7. 7 Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada. 8. 8 Dermatrials Research & Venderm Innovations in Psoriasis. Hamilton, ON, Canada. 9. 9 University of Calgary, Calgary, AB, Canada.
Abstract
BACKGROUND: Acitretin has been used for the treatment of severe psoriasis for over 20 years. OBJECTIVE: The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation. METHODS: A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. A panel of Canadian dermatologists developed a clinical pathway using a case-based approach, focusing on specific patient features. RESULTS: The clinical pathway covers plaque psoriasis with hyperkeratotic plantar disease, palmoplantar pustulosis, hyperkeratotic hand dermatitis, lichen planus, lamellar ichthyosis, and hidradenitis suppurativa. CONCLUSION: The recommendations in our clinical pathway reflect the current use of acitretin in Canada for severe psoriasis and other disorders of keratinisation.
BACKGROUND: Acitretin has been used for the treatment of severe psoriasis for over 20 years. OBJECTIVE: The current project was conceived to optimise patient care by recognising the role acitretin can play in the treatment of patients with psoriasis and those with other disorders of keratinisation. METHODS: A literature review was conducted to explore the role of acitretin and to assess its value for dermatologic disorders other than severe psoriasis. A panel of Canadian dermatologists developed a clinical pathway using a case-based approach, focusing on specific patient features. RESULTS: The clinical pathway covers plaque psoriasis with hyperkeratotic plantar disease, palmoplantar pustulosis, hyperkeratotic hand dermatitis, lichen planus, lamellar ichthyosis, and hidradenitis suppurativa. CONCLUSION: The recommendations in our clinical pathway reflect the current use of acitretin in Canada for severe psoriasis and other disorders of keratinisation.
Authors: Renan Tironi Giglio de Oliveira; Giovana Larissa Prado Leite Agostinho; Rubens Granja; Luiza Keiko M Oyafuso; Paulo Ricardo Criado Journal: An Bras Dermatol Date: 2021-01-30 Impact factor: 1.896
Authors: Maxim V Kuleshov; Daniel J Stein; Daniel J B Clarke; Eryk Kropiwnicki; Kathleen M Jagodnik; Alon Bartal; John E Evangelista; Jason Hom; Minxuan Cheng; Allison Bailey; Abigail Zhou; Laura B Ferguson; Alexander Lachmann; Avi Ma'ayan Journal: Patterns (N Y) Date: 2020-07-25